金吾财讯 | 汇丰研究发表报告指，随着带量采购的影响减低，康哲药业(00867)上半年业绩表现理想，收入及盈利分别增加11%和3%，胜于该机构预期。该机构上调康哲药业2025至27年的盈测1%至3%，又提到公司股价于年内升幅远远跑赢恒指，可能是由于其创新药销售增长前景乐观，但目前股价以2026年预测市盈率15倍交易，料2025至27的纯利年复合年均增长率超过20%，因此该股仍具吸引力。该机构预计，公司推出的创新药和销量提升将带来其更大上升空间，将目标价由16.1港元调升至16.8港元，维持买入评级，预期公司2025至27年的收入达83亿、100亿和127亿元人民币，利润分别达17亿、20亿和25亿元人民币。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.